Vnitr Lek 2008, 54(1):12-13

Fibrilace síní - kardiovaskulární epidemie - editorial

R. Lábrová
Interní kardiologická klinika LF MU a FN Brno, pracoviště Bohunice, přednosta prof. MUDr. Jindřich Špinar, CSc., FESC

Received: August 31, 2007; Published: January 1, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Lábrová R. Fibrilace síní - kardiovaskulární epidemie - editorial. Vnitr Lek. 2008;54(1):12-13.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Fuster V, Ryden LE, Cannom DS et al. ACC/AHA/ESC 2006 quidelines for the management of patients with atrial fibrillation - executive summary. Eur Heart J 2006; 27: 1976-2030. Go to original source...
    2. Gersh BJ, Tsang TSM, Seward JB. The changing epidemiology and natural history of nonvalvular atrial fibrillation: clinical implications. Trans Am Clin Climatol Assoc 2004; 114: 149-160.
    3. Go AS, Hylek EM, Phillips KA et al. Prevalence of diagnosed atrial fibrillation in adults. National implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285: 2370-2375. Go to original source... Go to PubMed...
    4. Furberg C, Psaty BM, Manolio TA et al. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol 1994; 74: 236-241. Go to original source... Go to PubMed...
    5. Tsang TS, Petty GW, Barnes ME et al. The prevalence of atrial fibrillation in incident stroke cases and matched population controls in Rochester, Minnesota: changes over three decades. J Am Coll Cardiol 2003; 42: 93-100. Go to original source... Go to PubMed...
    6. Blackshear JL, Kopecky SL, Litin SC et al. Management of atrial fibrillation in adults: prevention of thromboembolism and symptomatic treatment. Mayo Clin Proc 1996; 71: 150-160. Go to original source... Go to PubMed...
    7. Page RL, Wilkinson WE, Clair WK et al. Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial Fibrillation and paroxysmal supraventricular tachycardia. Circulation 1994; 89: 224-227. Go to original source... Go to PubMed...
    8. Israel CW, Gronefeld G, Ehrlich JR et al. Long-term risk of recurrent atrial fibrillation as documented by an implantable monitoring device: implications for optimal patient care. J Am Coll Cardiol 2004; 43: 47-52. Go to original source... Go to PubMed...
    9. Krahn AD, Manfreda J, Tate RB et al. The natural history of atrial fibrillation: incidence, Risk factors and prognosis in the Manitoba Follow-up Study. Am J Med 1995; 98: 476-484. Go to original source... Go to PubMed...
    10. Atrial Fibrillation Investigators Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized, controlled trials. Arch Intern Med 1994; 154: 1449-1457.
    11. SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators. Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III Study. JAMA 1998; 279: 1273-1277. Go to original source... Go to PubMed...
    12. Ruigomez A, Johansson S, Wallander MA et al. Incidence of chronic atrial fibrillation in general practice and its treatment pattern. J Clin Epidemiol 2002; 55: 358-363. Go to original source... Go to PubMed...
    13. Špinar J, Vítovec J. Losartan - víc než pokles krevního tlaku. Kardiol Rev 2006; 8: 115-120.

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.